Figure 3.
Morphological changes of (A) Hep3B cells after the 48 h treatment with compound 5 (at 1.8 μM), in comparison with (B) the vehicle control (DMSO) and (C) the positive control, doxorubicin (Dox, at 1.8 μM). Cancer cells showed shrinkage after the treatment of compound 5 and doxorubicin. The cells were stained by crystal violet. Each treatment was repeated in technical triplicates.
